Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956370 | 0.88 | NCF1 (0.43) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL3956166 | 0.80 | GNAO1 (0.41) | GNAI3GNAO1GNAI1HRH3HTR4 | |
| SCHEMBL3950352 | 0.79 | SMN1; SMN2 (0.41) | GNAO1HRH3ALDH1A1HTR4 | |
| SCHEMBL1851883 | 0.78 | NCF1 (0.46) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL24319800 | 0.78 | NCF1 (0.62) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL98083 | 0.78 | — | — | |
| SCHEMBL3947826 | 0.78 | NCF1 (0.42) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL1275989 | 0.77 | NCF1 (0.50) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL3956282 | 0.76 | SLC18A3 (0.39) | ACHEHRH3ALDH1A1 | |
| SCHEMBL3950205 | 0.76 | EPHX2 (0.39) | GNAI3GNAO1GNAI1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER (US) | 2017-09-28 | — | — | US | disclosed |
| CN-101679410-B | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2013-11-27 | — | — | CN | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN2B | NCF1 3178/4885ACHE 569/4885GNAI3 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.